# A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

> **NCT01689519** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 495 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Placebo
- **DRUG:** Vemurafenib
- **DRUG:** Cobimetinib

## Key facts

- **NCT ID:** NCT01689519
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-08
- **Primary completion:** 2014-05-09
- **Final completion:** 2019-07-21
- **Target enrollment:** 495 (ACTUAL)
- **Last updated:** 2022-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01689519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01689519, "A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01689519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*